Diabetes Drugmaker
- All
- News
-
Google Parent Alphabet and French Drugmaker Sanofi Set Up Diabetes Joint Venture
The venture, called Onduo, will initially focus on type two diabetes, the more common form of the disease.
-
Novartis and Google to Develop 'Smart' Contact Lens
Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics track their blood glucose levels or restore the eye's ability to focus.
-
India Caps Prices of 108 More Medicines; Drugmakers to Take Hit
India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.
-
Diabetes drug maker hid test data on risks, files indicate
In the fall of 1999, the drug giant SmithKline Beecham secretly began a study to find out if its diabetes medicine, Avandia, was safer for the heart than a competing pill, Actos, made by Takeda. Avandia's success was crucial to SmithKline, whose labs were otherwise all but barren of new products. But the study's results, completed that same year, w...
-
Google Parent Alphabet and French Drugmaker Sanofi Set Up Diabetes Joint Venture
The venture, called Onduo, will initially focus on type two diabetes, the more common form of the disease.
-
Novartis and Google to Develop 'Smart' Contact Lens
Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics track their blood glucose levels or restore the eye's ability to focus.
-
India Caps Prices of 108 More Medicines; Drugmakers to Take Hit
India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.
-
Diabetes drug maker hid test data on risks, files indicate
In the fall of 1999, the drug giant SmithKline Beecham secretly began a study to find out if its diabetes medicine, Avandia, was safer for the heart than a competing pill, Actos, made by Takeda. Avandia's success was crucial to SmithKline, whose labs were otherwise all but barren of new products. But the study's results, completed that same year, w...
